KEVIN GAREY to Pyridines
This is a "connection" page, showing publications KEVIN GAREY has written about Pyridines.
Connection Strength
0.507
-
Ridinilazole for the treatment of Clostridioides difficile infection. Expert Opin Investig Drugs. 2019 Apr; 28(4):303-310.
Score: 0.143
-
Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug; 48(2):137-43.
Score: 0.118
-
Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother. 2016 May; 71(5):1245-51.
Score: 0.116
-
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 06 14; 78(6):1462-1472.
Score: 0.052
-
The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic. Antimicrob Agents Chemother. 2023 05 17; 67(5):e0156322.
Score: 0.048
-
Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol. 2017 01; 33(1):1-7.
Score: 0.031